Molecular diversity in uterine carcinosarcoma: Beyond TP53

Area of Science:

• Genomics
• Oncology
• Molecular Pathology

Background:

• Uterine carcinosarcoma (UCS) is a rare and aggressive uterine malignancy.
• Understanding the molecular landscape of UCS is crucial for developing targeted therapies.

Purpose of the Study:

• To perform comprehensive genomic profiling of uterine carcinosarcoma (UCS).
• To identify actionable molecular alterations and therapeutic targets.
• To investigate the molecular relationship between the carcinomatous and sarcomatous components.

Main Methods:

• Next-generation sequencing of tumor DNA from 51 UCS patients.
• Analysis of genomic alterations, microsatellite instability, tumor mutational burden (TMB), and homologous recombination deficiency (HRD).
• Univariate Cox regression for survival analysis.

Main Results:

• TP53 mutations were found in 88% of cases, with PIK3CA and CCNE1 alterations also frequent.
• A TP53-mutant profile characterized the majority (84.6%) of UCS.
• Potential therapeutic targets were identified in 88% of cases; 14% had high TMB.
• Carcinoma and sarcoma components showed concordant gene variants but divergent copy number variations, suggesting a monoclonal origin.

Conclusions:

• Uterine carcinosarcoma (UCS) is molecularly heterogeneous, predominantly featuring TP53 mutations.
• Genomic profiling identified potential targets for existing therapies, highlighting the value of molecular sequencing in guiding UCS treatment.
• The study confirmed a monoclonal origin for UCS.